Form 4: Rapport Therapeutics Chief Medical Officer Reports Stock Option Grant

Jeffrey Sevigny, Chief Medical Officer of Rapport Therapeutics, reports the acquisition of stock options for 300,000 shares on April 1, 2025.

Summary

• Jeffrey Sevigny, the Chief Medical Officer of Rapport Therapeutics, filed a Form 4 with the SEC.
• The filing reports a transaction on April 1, 2025, where Sevigny acquired stock options for 300,000 shares of Rapport Therapeutics common stock.
• The exercise price of the stock options is $9.56 per share.
• The options vest over time, with 25% vesting on March 3, 2026, and the remaining shares vesting in 36 equal monthly installments thereafter, contingent upon continued service.
• The options expire on April 1, 2035.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing indicating standard executive compensation practices. It's neutral to slightly positive as it suggests the company is incentivizing its leadership.

Positives

• The grant of stock options to the Chief Medical Officer aligns his interests with those of the shareholders, incentivizing him to contribute to the company's success.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the pharmaceutical and biotechnology industries.
• Companies like Amgen, Biogen, and Gilead Sciences also utilize stock options to incentivize their executives.
• The vesting schedule and exercise price are typical for such grants, designed to reward long-term performance and commitment.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it aligns management's interests with the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

Form 4, Stock Options, Rapport Therapeutics, Insider Trading, Beneficial Ownership, Sevigny, RAPP, Chief Medical Officer